254 related articles for article (PubMed ID: 12907212)
1. Herceptin in patients with advanced or metastatic salivary gland carcinomas. A phase II study.
Haddad R; Colevas AD; Krane JF; Cooper D; Glisson B; Amrein PC; Weeks L; Costello R; Posner M
Oral Oncol; 2003 Oct; 39(7):724-7. PubMed ID: 12907212
[TBL] [Abstract][Full Text] [Related]
2. Salivary duct carcinoma--a highly aggressive salivary gland tumor with HER-2/neu oncoprotein overexpression.
Skálová A; Stárek ; Kucerová V; Szépe P; Plank L
Pathol Res Pract; 2001; 197(9):621-6. PubMed ID: 11569926
[TBL] [Abstract][Full Text] [Related]
3. Phase II study of weekly intravenous trastuzumab (Herceptin) in patients with HER2/neu-overexpressing metastatic breast cancer.
Baselga J; Tripathy D; Mendelsohn J; Baughman S; Benz CC; Dantis L; Sklarin NT; Seidman AD; Hudis CA; Moore J; Rosen PP; Twaddell T; Henderson IC; Norton L
Semin Oncol; 1999 Aug; 26(4 Suppl 12):78-83. PubMed ID: 10482197
[TBL] [Abstract][Full Text] [Related]
4. HER2/neu expression in adenoid cystic carcinoma of salivary gland origin: an immunohistochemical study.
Dori S; Vered M; David R; Buchner A
J Oral Pathol Med; 2002 Sep; 31(8):463-7. PubMed ID: 12220353
[TBL] [Abstract][Full Text] [Related]
5. Evaluation of monoclonal humanized anti-HER2 antibody, trastuzumab, in patients with recurrent or refractory ovarian or primary peritoneal carcinoma with overexpression of HER2: a phase II trial of the Gynecologic Oncology Group.
Bookman MA; Darcy KM; Clarke-Pearson D; Boothby RA; Horowitz IR
J Clin Oncol; 2003 Jan; 21(2):283-90. PubMed ID: 12525520
[TBL] [Abstract][Full Text] [Related]
6. Trastuzumab, an appropriate first-line single-agent therapy for HER2-overexpressing metastatic breast cancer.
Arteaga CL
Breast Cancer Res; 2003; 5(2):96-100. PubMed ID: 12631388
[TBL] [Abstract][Full Text] [Related]
7. Overview of the trastuzumab (Herceptin) anti-HER2 monoclonal antibody clinical program in HER2-overexpressing metastatic breast cancer. Herceptin Multinational Investigator Study Group.
Shak S
Semin Oncol; 1999 Aug; 26(4 Suppl 12):71-7. PubMed ID: 10482196
[TBL] [Abstract][Full Text] [Related]
8. First-line Herceptin monotherapy in metastatic breast cancer.
Vogel CL; Cobleigh MA; Tripathy D; Gutheil JC; Harris LN; Fehrenbacher L; Slamon DJ; Murphy M; Novotny WF; Burchmore M; Shak S; Stewart SJ
Oncology; 2001; 61 Suppl 2():37-42. PubMed ID: 11694786
[TBL] [Abstract][Full Text] [Related]
9. Interaction between Herceptin and taxanes.
Diéras V; Beuzeboc P; Laurence V; Pierga JY; Pouillart P
Oncology; 2001; 61 Suppl 2():43-9. PubMed ID: 11694787
[TBL] [Abstract][Full Text] [Related]
10. Herceptin alone or in combination with chemotherapy in the treatment of HER2-positive metastatic breast cancer: pivotal trials.
Baselga J
Oncology; 2001; 61 Suppl 2():14-21. PubMed ID: 11694783
[TBL] [Abstract][Full Text] [Related]
11. Overview of treatment results with trastuzumab (Herceptin) in metastatic breast cancer.
Hortobagyi GN
Semin Oncol; 2001 Dec; 28(6 Suppl 18):43-7. PubMed ID: 11774205
[TBL] [Abstract][Full Text] [Related]
12. Clinical utility of serum HER2/neu in monitoring and prediction of progression-free survival in metastatic breast cancer patients treated with trastuzumab-based therapies.
Esteva FJ; Cheli CD; Fritsche H; Fornier M; Slamon D; Thiel RP; Luftner D; Ghani F
Breast Cancer Res; 2005; 7(4):R436-43. PubMed ID: 15987448
[TBL] [Abstract][Full Text] [Related]
13. Trastuzumab treatment in patients with advanced or recurrent endometrial carcinoma overexpressing HER2/neu.
Santin AD; Bellone S; Roman JJ; McKenney JK; Pecorelli S
Int J Gynaecol Obstet; 2008 Aug; 102(2):128-31. PubMed ID: 18555254
[TBL] [Abstract][Full Text] [Related]
14. Clinical trials of single-agent trastuzumab (Herceptin).
Baselga J
Semin Oncol; 2000 Oct; 27(5 Suppl 9):20-6. PubMed ID: 11049053
[TBL] [Abstract][Full Text] [Related]
15. Metastatic HER-2-positive salivary gland carcinoma treated with trastuzumab and a taxane: a series of six patients.
De Block K; Vander Poorten V; Dormaar T; Nuyts S; Hauben E; Floris G; Deroose CM; Schöffski P; Clement PM
Acta Clin Belg; 2016 Dec; 71(6):383-388. PubMed ID: 27285571
[TBL] [Abstract][Full Text] [Related]
16. HER2 expression in salivary gland carcinomas: dependence on histological subtype.
Glisson B; Colevas AD; Haddad R; Krane J; El-Naggar A; Kies M; Costello R; Summey C; Arquette M; Langer C; Amrein PC; Posner M
Clin Cancer Res; 2004 Feb; 10(3):944-6. PubMed ID: 14871971
[TBL] [Abstract][Full Text] [Related]
17. The role of trastuzumab in the management of salivary ductal carcinomas.
Perissinotti AJ; Lee Pierce M; Pace MB; El-Naggar A; Kies MS; Kupferman M
Anticancer Res; 2013 Jun; 33(6):2587-91. PubMed ID: 23749912
[TBL] [Abstract][Full Text] [Related]
18. Phase II trial of trastuzumab followed by weekly paclitaxel/carboplatin as first-line treatment for patients with metastatic breast cancer.
Burris H; Yardley D; Jones S; Houston G; Broome C; Thompson D; Greco FA; White M; Hainsworth J
J Clin Oncol; 2004 May; 22(9):1621-9. PubMed ID: 15117984
[TBL] [Abstract][Full Text] [Related]
19. HER-2/neu status of primary breast cancer and corresponding metastatic sites in patients with advanced breast cancer treated with trastuzumab-based therapy.
Pectasides D; Gaglia A; Arapantoni-Dadioti P; Bobota A; Valavanis C; Kostopoulou V; Mylonakis N; Karabelis A; Pectasides M; Economopoulos T
Anticancer Res; 2006; 26(1B):647-53. PubMed ID: 16739334
[TBL] [Abstract][Full Text] [Related]
20. Significant and durable clinical benefit from trastuzumab in 2 patients with HER2-amplified salivary gland cancer and a review of the literature.
Thorpe LM; Schrock AB; Erlich RL; Miller VA; Knost J; Le-Lindqwister N; Jujjavarapu S; Ali SM; Liu JJ
Head Neck; 2017 Mar; 39(3):E40-E44. PubMed ID: 28006087
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
